The UK News Archive contains resources intended for journalists only.
News Archive
Showing 20 results
February 2023
-
Media ReleaseNovartis UK response to NICE second Appraisal Consultation Document (ACD) for Pluvicto®▼ (lutetium (177Lu) vipivotide tetraxetan) for advanced prostate cancerNovartis UK welcomes the opportunity to continue to work with NICE following the publication of a second Appraisal Consultation Document (ACD) for Pluvicto®▼ (lutetium (177Lu) vipivotide tetraxetan)…
-
Media ReleaseNovartis UK Update on Estradot SupplyNovartis UK confirms that we will go out of stock on ESTRADOT TTS-50, ESTRADOT TTS-100, and ESTRADOT TTS-25. Based on our current information, we expect that these presentations of Estradot will…
July 2022
-
Media ReleaseNICE recommends Novartis Beovu® (brolucizumab) for thousands with sight loss due to diabetesBeovu® (brolucizumab) can improve visual impairment due to diabetic macular oedema1 Brolucizumab can help minimise treatment burden with evidence suggesting it may be administered less…
-
Media ReleaseNICE recommends Novartis’ Piqray ® (alpelisib) as a targeted treatment for thousands of advanced breast cancer patientsAround 2,800 advanced breast cancer patients in England and Wales could now benefit from alpelisib on the NHS after a recommendation from the National Institute for Health and Care Excellence (NICE)1…
-
Media ReleaseScottish Medicines Consortium issues interim acceptance to Novartis’ Adakveo®▼ (crizanlizumab) for preventing recurrent vaso-occlusive crises, the first treatment for sickle cell disorder in over 20 yearsAdakveo® (crizanlizumab) receives interim acceptance by the Scottish Medicines Consortium (SMC) for preventing recurrent sickle cell crises (vaso- occlusive crises, VOCs) in people aged 16 or older…
-
Media ReleaseNovartis Pharmaceuticals UK launches world-first health-tech investor partnership to reimagine cardiovascular careLondon, 05 July 2022 — Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset…